Table 1.
Background of the subjects
| BRVO | CRVO | |
|---|---|---|
| Number of eyes | 19 | 9 |
| Gender (male/female) | 5/14 | 7/2 |
| Age (years) | 72.4 ± 7.7 | 74.1 ± 8.2 |
| Hypertension | 6 | 7 |
| Diabetes | 4 | 1 |
| Fluorescein angiography (ischemic/nonischemic) | 11/8 | 0/9 |
| Before initial IVB | ||
| Visual acuity (logMAR) | 0.66 ± 0.35 | 0.91 ± 0.38 |
| Foveal thickness (μm) | 656.5 ± 179.1 | 780.8 ± 148.5 |
| Number of IVB (once/twice) | 13/6 | 9/0 |
| Baseline | ||
| Visual acuity (logMAR) | 0.53 ± 0.34 | 0.81 ± 0.29 |
| Foveal thickness (μm) | 518.4 ± 112.5 | 588.6 ± 118.4 |
| Duration between initial IVB and baseline (months) | 8.1 ± 3.9 | 4.4 ± 1.5 |
| Follow-up (months) | 22.0 ± 6.1 | 23.3 ± 4.8 |
Abbreviations: BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion; IVB, intravitreal injection of bevacizumab; ischemic BRVO, showing >5 disc diameters of nonperfusion area; ischemic CRVO, showing >10 disc areas of nonperfusion; logMAR, logarithm of the minimum angle of resolution.